US Stock MarketDetailed Quotes
WVE Wave Life Sciences
- 5.740
- +0.220+3.99%
Close Aug 23 16:00 ET
- 5.610
- -0.130-2.26%
Post 20:01 ET
716.00MMarket Cap-10070P/E (TTM)
5.800High5.490Low724.78KVolume5.570Open5.520Pre Close4.14MTurnover1.33%Turnover RatioLossP/E (Static)124.74MShares7.67052wk High-205.00P/B313.12MFloat Cap3.50052wk Low--Dividend TTM54.55MShs Float56.000Historical High--Div YieldTTM5.62%Amplitude1.160Historical Low5.716Avg Price1Lot Size
Wave Life Sciences Stock Forum
Sign in to post a comment
$Wave Life Sciences (WVE.US)$ Benzinga· 1 min ago
Wave Life Sciences Announces FDA Has Granted Rare Pediatric Disease Designation To WVE-N531 For Treatment Of Duchenne Muscular Dystrophy
Wave Life Sciences Announces FDA Has Granted Rare Pediatric Disease Designation To WVE-N531 For Treatment Of Duchenne Muscular Dystrophy
2
$Wave Life Sciences (WVE.US)$ got to love when good news tanks the price lol
$Wave Life Sciences (WVE.US)$
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Wave Life Sciences announced positive results from their Phase 1b/2a SELECT-HD trial for WVE-003, a therapeutic for Huntington's disease (HD). The trial showed a statistically significant 46% reduction in mutant huntingtin (mHTT) protein in the cerebrospinal fluid compared to placeb...
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Wave Life Sciences announced positive results from their Phase 1b/2a SELECT-HD trial for WVE-003, a therapeutic for Huntington's disease (HD). The trial showed a statistically significant 46% reduction in mutant huntingtin (mHTT) protein in the cerebrospinal fluid compared to placeb...
1
$Wave Life Sciences (WVE.US)$
NEWS
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Wave Life Sciences announces continued momentum in GSK collaboration with the selection of two programs for development, initiation of clinical trials for the INHBE program in obesity, and upcoming presentations at key conferences. GSK collaboration progresses with an aggregate initiation payment of $12 million for two oligonucleotide programs using Wav...
NEWS
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Wave Life Sciences announces continued momentum in GSK collaboration with the selection of two programs for development, initiation of clinical trials for the INHBE program in obesity, and upcoming presentations at key conferences. GSK collaboration progresses with an aggregate initiation payment of $12 million for two oligonucleotide programs using Wav...
Investors' optimism about strong revenue performance may have led to a high P/S ratio. However, with forecasted revenue decline, this high ratio may not be sustainable, posing a risk to shareholders and potential investors.
Wave Life Sciences Ltd.'s high P/S ratio may be worrisome due to expected revenue shrinkage. Current investors could face disappointment if the P/S ratio aligns with the negative growth forecast, putting their investments at risk and potential investors may overpay.
Company's low cash burn relative to market cap allows easy fund-raising for growth. Noteworthy decrease in cash burn, paired with significant revenue growth, shows solid spending control, easing concerns about cash burn.
$Wave Life Sciences (WVE.US)$ Wave Life Sciences Q3 2023 EPS $0.07 Beats $(0.18) Estimate, Revenue $49.21M Beats $23.43M Estimate![]()
$Wave Life Sciences (WVE.US)$ After investors meeting and update on pipeline. This has some very encouraging datasets? moving forward IMO this could be big? ![]()
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
买跌不追涨 : This news is great, but there is still no response
Trytosaveabit OP 买跌不追涨 : Market isn’t open! We will see if it does then? GL